CL2019003251A1 - Alfa-glucosidasa ácida humana recombinante. - Google Patents

Alfa-glucosidasa ácida humana recombinante.

Info

Publication number
CL2019003251A1
CL2019003251A1 CL2019003251A CL2019003251A CL2019003251A1 CL 2019003251 A1 CL2019003251 A1 CL 2019003251A1 CL 2019003251 A CL2019003251 A CL 2019003251A CL 2019003251 A CL2019003251 A CL 2019003251A CL 2019003251 A1 CL2019003251 A1 CL 2019003251A1
Authority
CL
Chile
Prior art keywords
glucosidase
acid alpha
alpha
recombinant
recombinant human
Prior art date
Application number
CL2019003251A
Other languages
English (en)
Inventor
Hing Char
Sergey Tesler
Wendy Sunderland
Enrique Diloné
Hung Do
Russell Gotschall
Richie Khanna
Yi Lun
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CL2019003251A1 publication Critical patent/CL2019003251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONA UNA ALFA-GLUCOSIDASA ÁCIDA RECOMBINANTE Y COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA ALFA-GLUCOSIDASA ÁCIDA RECOMBINANTE, EN DONDE LA ALFA-GLUCOSIDASA ÁCIDA RECOMBINANTE SE EXPRESA EN CÉLULAS DERIVADAS DE OVARIO DE HÁMSTER CHINO (CHO) Y COMPRENDE UN CONTENIDO AUMENTADO DE UNIDADES DE N-GLUCANO QUE PORTAN UNO O MÁS RESIDUOS DE MANOSA-6- FOSFATO EN COMPARACIÓN CON UN CONTENIDO DE UNIDADES DE N-GLUCANO QUE PORTAN UNO O DOS RESIDUOS DE MANOSA-6-FOSFATO DE ALFA GLUCOSIDASA. TAMBIÉN SE PROPORCIONAN MÉTODOS PARA PRODUCIR, PURIFICAR Y FORMULAR LA ALFA-GLUCOSIDASA ÁCIDA RECOMBINANTE O COMPOSICIÓN FARMACÉUTICA PARA ADMINISTRACIÓN A UN SUJETO Y MÉTODOS PARA TRATAR UNA ENFERMEDAD O TRASTORNO COMO ENFERMEDAD DE POMPE USANDO LA ALFA-GLUCOSIDASA ÁCIDA RECOMBINANTE O COMPOSICIÓN FARMACÉUTICA.
CL2019003251A 2017-05-15 2019-11-13 Alfa-glucosidasa ácida humana recombinante. CL2019003251A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762506574P 2017-05-15 2017-05-15
US201762506561P 2017-05-15 2017-05-15
US201762506569P 2017-05-15 2017-05-15
US201762529300P 2017-07-06 2017-07-06
US201762564083P 2017-09-27 2017-09-27
US201762567334P 2017-10-03 2017-10-03
US201862618021P 2018-01-16 2018-01-16
US201862624638P 2018-01-31 2018-01-31
US201862660758P 2018-04-20 2018-04-20

Publications (1)

Publication Number Publication Date
CL2019003251A1 true CL2019003251A1 (es) 2020-05-22

Family

ID=64274660

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003251A CL2019003251A1 (es) 2017-05-15 2019-11-13 Alfa-glucosidasa ácida humana recombinante.

Country Status (25)

Country Link
US (2) US12246062B2 (es)
EP (2) EP4223310A3 (es)
JP (3) JP7193476B2 (es)
KR (2) KR20250044950A (es)
CN (3) CN119113091A (es)
AU (2) AU2018270925B2 (es)
BR (1) BR112019024125A2 (es)
CA (1) CA3063615A1 (es)
CL (1) CL2019003251A1 (es)
DK (1) DK3624831T5 (es)
ES (1) ES2950808T3 (es)
FI (1) FI3624831T3 (es)
HR (1) HRP20230576T1 (es)
HU (1) HUE062504T2 (es)
IL (2) IL270530B2 (es)
LT (1) LT3624831T (es)
MX (3) MX2019013624A (es)
PL (1) PL3624831T3 (es)
PT (1) PT3624831T (es)
RS (1) RS64301B1 (es)
SI (1) SI3624831T1 (es)
SM (1) SMT202300187T1 (es)
TW (2) TW202448499A (es)
WO (1) WO2018213340A1 (es)
ZA (1) ZA201907552B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
US20240197839A1 (en) * 2021-02-11 2024-06-20 Amicus Therapeutics, Inc. Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
CN114280182A (zh) * 2021-12-23 2022-04-05 福建省中医药科学院 一种太子参均一多糖的hplc-fld检测方法
US20250134967A1 (en) * 2022-02-07 2025-05-01 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
AU2023265155A1 (en) * 2022-05-05 2024-12-12 Amicus Therapeutics, Inc. Methods for treating pompe disease
EP4626464A1 (en) * 2022-12-02 2025-10-08 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients
KR20250113510A (ko) * 2022-12-02 2025-07-25 아미쿠스 세라퓨틱스, 인코포레이티드 소아 환자의 후기 발병 폼페병 치료에 대한 방법
WO2026004963A1 (ja) * 2024-06-26 2026-01-02 三菱ケミカル株式会社 分離材、分離材の製造方法、標的分子の分離方法、混合物、及びクロマトグラフィー用カラム

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US20020073438A1 (en) 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
CA2353522A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
ATE402701T1 (de) 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK1782825T3 (da) 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
PT2857036T (pt) 2003-01-31 2017-03-13 Mount Sinai School Of Medicine Of N Y Univ Terapia combinada para o tratamento de distúrbios de deficiência proteica
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
CA2669347A1 (en) 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2009114712A2 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for pompe disease
EP2252325A4 (en) 2008-03-12 2012-07-11 Amicus Therapeutics Inc TREATMENT OF MORBUS POMPE WITH SPECIFIC PHARMACOLOGICAL CHAPTERONES AND TREATMENT MONITORING WITH SURROGATE MARKERS
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
PL2889043T3 (pl) 2008-12-16 2019-09-30 Genzyme Corporation Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
US8466340B2 (en) 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
BRPI1010517A2 (pt) 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
WO2010138608A1 (en) 2009-05-26 2010-12-02 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US9427033B2 (en) 2009-12-16 2016-08-30 Under Armour, Inc. Athletic arm warmer
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2012042386A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
RU2013151875A (ru) 2011-04-22 2015-05-27 Джензим Корпорейшн Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013070953A1 (en) 2011-11-08 2013-05-16 University Of Washington Lysosomal enzyme assay methods and compositions
ES2864774T3 (es) 2011-12-22 2021-10-14 Centogene Ip Gmbh Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
JP6194324B2 (ja) 2012-03-15 2017-09-06 オキシレイン ユーケー リミテッド ポンペ病の処置のための方法および材料
EP2844279B1 (en) 2012-05-03 2020-12-09 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
WO2014110270A1 (en) * 2013-01-09 2014-07-17 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
WO2015097088A1 (en) 2013-12-23 2015-07-02 Bcn Peptides, S.A. Bicalutamide analogs or (s)-bi calutam ide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
WO2017049161A1 (en) 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
KR102747683B1 (ko) 2015-12-30 2024-12-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase

Also Published As

Publication number Publication date
EP3624831A4 (en) 2021-02-17
RS64301B1 (sr) 2023-07-31
PL3624831T3 (pl) 2023-08-14
ES2950808T3 (es) 2023-10-13
EP3624831B1 (en) 2023-03-29
DK3624831T5 (da) 2024-09-02
ZA201907552B (en) 2024-09-25
WO2018213340A1 (en) 2018-11-22
EP4223310A2 (en) 2023-08-09
IL310719A (en) 2024-04-01
PT3624831T (pt) 2023-07-04
CA3063615A1 (en) 2018-11-22
EP3624831A1 (en) 2020-03-25
HUE062504T2 (hu) 2023-11-28
EP4223310A3 (en) 2023-10-11
MX2024015740A (es) 2025-02-10
CN119139461A (zh) 2024-12-17
HRP20230576T1 (hr) 2023-09-01
JP2020519638A (ja) 2020-07-02
US20210393747A1 (en) 2021-12-23
CN119113091A (zh) 2024-12-13
IL270530B1 (en) 2024-03-01
US20250057925A1 (en) 2025-02-20
KR20200004414A (ko) 2020-01-13
TWI870336B (zh) 2025-01-21
LT3624831T (lt) 2023-07-10
KR102787774B1 (ko) 2025-04-01
SI3624831T1 (sl) 2023-08-31
BR112019024125A2 (pt) 2020-06-02
DK3624831T3 (da) 2023-06-26
IL270530A (en) 2020-01-30
JP7193476B2 (ja) 2022-12-20
MX2019013624A (es) 2020-01-13
AU2025203557A1 (en) 2025-06-05
CN111356474A (zh) 2020-06-30
TW202448499A (zh) 2024-12-16
TW201900208A (zh) 2019-01-01
AU2018270925B2 (en) 2025-02-20
KR20250044950A (ko) 2025-04-01
SMT202300187T1 (it) 2023-07-20
AU2018270925A1 (en) 2019-11-28
US12246062B2 (en) 2025-03-11
IL270530B2 (en) 2024-07-01
JP2023051927A (ja) 2023-04-11
FI3624831T3 (fi) 2023-06-12
MX2024015741A (es) 2025-02-10
JP2025016455A (ja) 2025-02-04

Similar Documents

Publication Publication Date Title
MX2019013624A (es) Alfa-glucosidasa acida humana recombinante.
CO2018007680A2 (es) Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo
PE20211224A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
CO2018011349A2 (es) Formulaciones que comprenden alfa-glucosidasa ácida recombinante
MX2018011951A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
AR112706A1 (es) Productos terapéuticos para la glucogenosis tipo iii
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
CL2011001834A1 (es) Antucerpo o fragmento de union del mismo que se enlaza a interleuquina -1 alfa (il-1 alfa) humana; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para preparar un medicamento.
SV2017005416A (es) Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
BR112015021869A2 (pt) Domínios gla como agentes alvo
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
NI201300110A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
AR089852A1 (es) Anticuerpos anti-asic-1 y usos de los mismos
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
BR112015003851A2 (pt) composições compreendendo um domínio variável único e mesilato de camostato (cm)
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
EA201692126A1 (ru) Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан